MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announces that according to the analysis of the preliminary results during the ongoing year end closing process, MorphoSys' outlook has been exceeded.
Group revenues for 2020 are expected to amount to EUR 327.7 million and therefore slightly above the upper end of the guidance range from EUR 317 to 327 million. Group revenues include EUR 18.5 million (USD 22.0 million) revenues from product sales of Monjuvi as well as EUR 42.5 million for royalties on net sales of Tremfya. EBIT (Earnings before Interests and Taxes) for 2020 is expected to be EUR 27.4 million, and therefore significantly above the upper end of the guidance range of EUR 10 to 20 million. Expenses for research and development are expected to amount to EUR 141.4 million and therefore slightly above the guided range of EUR 130 to 140 million.
https://www.marketscreener.com/quote/stock/MORPHOSYS-AG-436425/news/MorphoSys-nbsp-Ad-hoc-MorphoSys-AG-preliminary-results-for-the-fiscal-year-2020-exceeding-guidanc-32582135/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.